{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:06:14Z","timestamp":1790701574638,"version":"4.1.0"},"reference-count":68,"publisher":"IMR Press","issue":"3","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Biosci. (Schol Ed)"],"abstract":"<jats:p>Multiple myeloma (MM) is a biologically and clinically heterogeneous plasma cell malignancy characterized by clonal expansion in the bone marrow and a highly variable clinical course. Despite major therapeutic advances, MM remains incurable, largely due to the associated genomic complexity, clonal evolution, and the emergence of treatment resistance. In this context, next-generation sequencing (NGS) has emerged as a transformative tool for improving disease characterization, risk stratification, and clinical management. This review summarizes current evidence on the application of NGS technologies, including whole-exome sequencing, whole-genome sequencing, and targeted gene panels\u2014in the diagnosis, prognostic assessment, and monitoring of MM. Genomic profiling has consistently revealed recurrent alterations in key driver genes, copy number abnormalities, and structural variants that underlie disease heterogeneity and influence clinical outcomes. In addition to baseline characterization, NGS enables high-resolution analysis of clonal architecture and evolution, offering critical insights into mechanisms of relapse and therapeutic resistance. Importantly, NGS-based assessment of minimal residual disease (MRD) has demonstrated superior sensitivity compared with conventional techniques, providing a powerful prognostic marker and a promising tool for treatment monitoring and response-adapted strategies. Indeed, by integrating genomic and MRD data, NGS supports a more precise and dynamic approach to patient management. Overall, the growing body of evidence highlights NGS as a central component of precision medicine in multiple myeloma. Continued efforts toward standardization, validation of emerging biomarkers, and clinical implementation of sequencing-guided strategies are expected to enhance personalized treatment further and improve patient outcomes.<\/jats:p>","DOI":"10.31083\/fbs44690","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:26:53Z","timestamp":1790699213000},"source":"Crossref","is-referenced-by-count":0,"title":["Next Generation Sequencing in the Diagnosis of Multiple Myeloma"],"prefix":"10.31083","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4570-3795","authenticated-orcid":true,"given":"Ikram","family":"EL Fazazi","sequence":"first","affiliation":[{"name":"Genetics Unit, Central Laboratory of Medical Analysis, Sidi Mohammed Ben Abdellah University, University Hospital Hassan II, 30050 Fez, Morocco"},{"name":"Human Pathologies, Biomedicine and Environment Laboratory, Faculty of Medicine, Pharmacy and Dentistry, Sidi Mohammed Ben Abdellah University, 30070 Fez, Morocco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0246-1439","authenticated-orcid":true,"given":"Hajar","family":"Ihlal","sequence":"additional","affiliation":[{"name":"Genetics Unit, Central Laboratory of Medical Analysis, Sidi Mohammed Ben Abdellah University, University Hospital Hassan II, 30050 Fez, Morocco"},{"name":"Human Pathologies, Biomedicine and Environment Laboratory, Faculty of Medicine, Pharmacy and Dentistry, Sidi Mohammed Ben Abdellah University, 30070 Fez, Morocco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Ouskri","sequence":"additional","affiliation":[{"name":"Genetics Unit, Central Laboratory of Medical Analysis, Sidi Mohammed Ben Abdellah University, University Hospital Hassan II, 30050 Fez, Morocco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Nmer","sequence":"additional","affiliation":[{"name":"Genetics Unit, Central Laboratory of Medical Analysis, Sidi Mohammed Ben Abdellah University, University Hospital Hassan II, 30050 Fez, Morocco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Washenko","sequence":"additional","affiliation":[{"name":"Genetics Unit, Central Laboratory of Medical Analysis, Sidi Mohammed Ben Abdellah University, University Hospital Hassan II, 30050 Fez, Morocco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4787-3100","authenticated-orcid":true,"given":"Hinde","family":"EL Mouhi","sequence":"additional","affiliation":[{"name":"Genetics Unit, Central Laboratory of Medical Analysis, Sidi Mohammed Ben Abdellah University, University Hospital Hassan II, 30050 Fez, Morocco"},{"name":"Biomedical and Translational Research Laboratory, Faculty of Medicine, Pharmacy, and Dental Medicine of Fez, Sidi Mohamed Ben Abdellah University, 30050 Fez, Morocco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4498-0085","authenticated-orcid":true,"given":"Meriame","family":"Abbassi","sequence":"additional","affiliation":[{"name":"Genetics Unit, Central Laboratory of Medical Analysis, Sidi Mohammed Ben Abdellah University, University Hospital Hassan II, 30050 Fez, Morocco"},{"name":"Now with The Higher Institute of Nursing Professions and Health Techniques, 30050 Fez, Morocco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0417-429X","authenticated-orcid":true,"given":"Mohamed","family":"Ahakoud","sequence":"additional","affiliation":[{"name":"Genetics Unit, Central Laboratory of Medical Analysis, Sidi Mohammed Ben Abdellah University, University Hospital Hassan II, 30050 Fez, Morocco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4082-5432","authenticated-orcid":true,"given":"Laila","family":"Bouguenouch","sequence":"additional","affiliation":[{"name":"Genetics Unit, Central Laboratory of Medical Analysis, Sidi Mohammed Ben Abdellah University, University Hospital Hassan II, 30050 Fez, Morocco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7801-8778","authenticated-orcid":true,"given":"Rhizlane","family":"Berrady","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Oncohematology, Sidi Mohammed Ben Abdellah University, CHU Hassan II, 30050 Fez, Morocco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3974-5889","authenticated-orcid":true,"given":"Karim","family":"Ouldim","sequence":"additional","affiliation":[{"name":"Genetics Unit, Central Laboratory of Medical Analysis, Sidi Mohammed Ben Abdellah University, University Hospital Hassan II, 30050 Fez, Morocco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1361-7902","authenticated-orcid":true,"given":"Mohammed","family":"El-Azami-El-Idrissi","sequence":"additional","affiliation":[{"name":"Genetics Unit, Central Laboratory of Medical Analysis, Sidi Mohammed Ben Abdellah University, University Hospital Hassan II, 30050 Fez, Morocco"},{"name":"Human Pathologies, Biomedicine and Environment Laboratory, Faculty of Medicine, Pharmacy and Dentistry, Sidi Mohammed Ben Abdellah University, 30070 Fez, Morocco"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Caulier A, Roussel M, Morel P, Lombion N, Branco B, Galtier J, et al. Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience. Blood. 2021; 138: 2686\u20132695.","DOI":"10.1182\/blood.2021011285"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Ho M, Patel A, Goh CY, Moscvin M, Zhang L, Bianchi G. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Leukemia. 2020; 34: 3111\u20133125.","DOI":"10.1038\/s41375-020-01051-x"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, et al. Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016. JAMA Oncology. 2018; 4: 1221\u20131227.","DOI":"10.1001\/jamaoncol.2018.2128"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Boyle EM, Williams L, Blaney P, Ashby C, Bauer M, Walker BA, et al. Improving prognostic assignment in older adults with multiple myeloma using acquired genetic features, clonal hemopoiesis and telomere length. Leukemia. 2022; 36: 221\u2013224.","DOI":"10.1038\/s41375-021-01320-3"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"DeStefano CB, Gibson SJ, Sperling AS, Richardson PG, Ghobrial I, Mo CC. The emerging importance and evolving understanding of clonal hematopoiesis in multiple myeloma. Seminars in Oncology. 2022; 49: 19\u201326.","DOI":"10.1053\/j.seminoncol.2022.01.009"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Marinac CR, Ghobrial IM, Birmann BM, Soiffer J, Rebbeck TR. Dissecting racial disparities in multiple myeloma. Blood Cancer Journal. 2020; 10: 19.","DOI":"10.1038\/s41408-020-0284-7"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Schinasi LH, Brown EE, Camp NJ, Wang SS, Hofmann JN, Chiu BC, et al. Multiple myeloma and family history of lymphohaematopoietic cancers: Results from the International Multiple Myeloma Consortium. British Journal of Haematology. 2016; 175: 87\u2013101.","DOI":"10.1111\/bjh.14199"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a Cancer Journal for Clinicians. 2021; 71: 209\u2013249.","DOI":"10.3322\/caac.21660"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Brigle K, Rogers B. Pathobiology and Diagnosis of Multiple Myeloma. Seminars in Oncology Nursing. 2017; 33: 225\u2013236.","DOI":"10.1016\/j.soncn.2017.05.012"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Busque L, Patel JP, Figueroa ME, Vasanthakumar A, Provost S, Hamilou Z. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nature Genetics. 2012; 44: 1179\u20131181.","DOI":"10.1038\/ng.2413"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Yohe S, Thyagarajan B. Review of Clinical Next-Generation Sequencing. Archives of Pathology & Laboratory Medicine. 2017; 141: 1544\u20131557.","DOI":"10.5858\/arpa.2016-0501-RA"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Pereira R, Oliveira J, Sousa M. Bioinformatics and Computational Tools for Next-Generation Sequencing Analysis in Clinical Genetics. Journal of Clinical Medicine. 2020; 9: 132.","DOI":"10.3390\/jcm9010132"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Paiva B, Garc\u00eda-Sanz R, San Miguel JF. Multiple Myeloma Minimal Residual Disease. Cancer Treatment and Research. 2016; 169: 103\u2013122.","DOI":"10.1007\/978-3-319-40320-5_7"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Bal S, Dhakal B, Silbermann RW, Schmidt TM, Dholaria B, Giri S, et al. Impact of autologous hematopoietic cell transplantation on disease burden quantified by next-generation sequencing in multiple myeloma treated with quadruplet therapy. American Journal of Hematology. 2022; 97: 1170\u20131177.","DOI":"10.1002\/ajh.26640"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Cho H, Shin S, Chung H, Jang JE, Kim YR, Cheong JW, et al. Real-world data on prognostic value of measurable residual disease assessment by fragment analysis or next-generation sequencing in multiple myeloma. British Journal of Haematology. 2022; 198: 503\u2013514.","DOI":"10.1111\/bjh.18211"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Kriegsmann K, Hundemer M, Hofmeister-Mielke N, Reichert P, Manta CP, Awwad MHS, et al. Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment. Cancers. 2020; 12: 2322.","DOI":"10.3390\/cancers12082322"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Urushihara R, Takezako N, Yoroidaka T, Yamashita T, Nakao S, Takamatsu H. Comparison of MRD detection in autografts in multiple myeloma between novel high-sensitivity EuroFlow-NGF and NGS. Blood. 2021; 138: 3950.","DOI":"10.1182\/blood-2021-149041"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Yoroidaka T, Takamatsu H, Itagaki M, Yoshihara S, Sato K, Takezako N, et al. Prospective Comparison Study of Prognostic Value of MRD Detected By 8-Color MFC (EuroFlow-NGF) and NGS in Patients with Multiple Myeloma in ASCT Setting. Blood. 2021; 138: 3946.","DOI":"10.1182\/blood-2021-146441"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Drandi D, Ferrero S, Ladetto M. Droplet Digital PCR for Minimal Residual Disease Detection in Mature Lymphoproliferative Disorders. In Karlin-Neumann G, Bizouarn F (eds.) Digital PCR (pp. 229\u2013256). Springer: New York, NY. 2018.","DOI":"10.1007\/978-1-4939-7778-9_14"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Galimberti S, Balducci S, Guerrini F, Del Re M, Cacciola R. Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool. Diagnostics (Basel, Switzerland). 2022; 12: 1305.","DOI":"10.3390\/diagnostics12061305"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Subhash VV, Huang L, Kamili A, Wong M, Chen D, Venn NC, et al. Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma. British Journal of Cancer. 2022; 126: 482\u2013491.","DOI":"10.1038\/s41416-021-01538-z"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Mishima Y, Paiva B, Shi J, Park J, Manier S, Takagi S, et al. The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. Cell Reports. 2017; 19: 218\u2013224.","DOI":"10.1016\/j.celrep.2017.03.025"},{"key":"ref23","unstructured":"Farswan A, Jena L, Kaur G, Gupta A, Gupta R, Rani L, et al. Branching clonal evolution patterns predominate mutational landscape in multiple myeloma. American Journal of Cancer Research. 2021; 11: 5659\u20135679."},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Kaur G, Gupta R, Jena L, Farswan A, Gupta A, Kumar L, et al. P-050: Whole Exome Sequencing provides novel insights in synonymous and non-synonymous mutational landscapes of Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia. 2021; 21: S65\u2013S66.","DOI":"10.1016\/S2152-2650(21)02184-4"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Kumar A, Adhikari S, Kankainen M, Heckman CA. Comparison of Structural and Short Variants Detected by Linked-Read and Whole-Exome Sequencing in Multiple Myeloma. Cancers. 2021; 13: 1212.","DOI":"10.3390\/cancers13061212"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Williams L, Blaney P, Boyle EM, Ghamlouch H, Wang Y, Choi J, et al. Hispanic or Latin American Ancestry Is Associated with a Similar Genomic Profile and a Trend Toward Inferior Outcomes in Newly Diagnosed Multiple Myeloma As Compared to Non-Hispanic White Patients in the Multiple Myeloma Research Foundation (MMRF) CoMMpass study. Blood. 2021; 138: 4117.","DOI":"10.1182\/blood-2021-148854"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"O\u2019Dwyer ME, Spencer A, Kumar SK, Popat R, Moreau P, Dail M, et al. Integrative Analysis of the Genomic and Transcriptomic Landscape of Relapsed\/Refractory Multiple Myeloma Patients Treated With Venetoclax in Combination With Bortezomib and Dexamethasone: Biomarker Analyses From the Phase 3 BELLINI Study. Blood. 2020; 136: 40\u201341.","DOI":"10.1182\/blood-2020-134710"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Song J, Zhang H, Zhang X, Hussaini M, Dong N, Moscinski LC, et al. Molecular Insights into Clonal Hematopoiesis and Therapy-Related Myeloid Neoplasm in Patients with Multiple Myeloma and Cytopenia(s). Blood. 2020; 136: 6\u20137.","DOI":"10.1182\/blood-2020-141656"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Ziccheddu B, Biancon G, De Philippis C, Bagnoli F, Maura F, Dugo M, et al. The genomic and transcriptomic landscape of double-refractory multiple myeloma. Blood. 2019; 134: 3056.","DOI":"10.1182\/blood-2019-122197"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Ziccheddu B, Biancon G, Dugo M, Devecchi A, De Philippis C, Bagnoli F, et al. Analysis of the genomic and transcriptomic landscape of chemoresistant multiple myeloma. Clinical Lymphoma Myeloma and Leukemia. 2019; 19: e58\u2013e59.","DOI":"10.1016\/j.clml.2019.09.091"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Ashby C, Wang Y, Tytarenko RG, Schinke CD, Thanendrarajan S, Zangari M, et al. Poor Overall Survival in Hyperhaploid Multiple Myeloma Is Defined By Double-Hit Bi-Allelic Inactivation of TP53. Blood. 2018; 132: 4441.","DOI":"10.1182\/blood-2018-99-113102"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Mouhieddine TH, Park J, Redd RA, Gibson CJ, Manier S, Nassar AH, et al. The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome. Blood. 2018; 132: 749.","DOI":"10.1182\/blood-2018-99-113059"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Bustoros M, Park J, Salem KZ, Liu CJ, Capelletti M, Huynh D, et al. Next Generation Sequencing Identifies Smoldering Multiple Myeloma Patients with a High Risk of Disease Progression. Blood. 2017; 130: 392.","DOI":"10.1182\/blood.V130.Suppl_1.392.392"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Dutta AK, Grady JP, Hewett DR, To LB, Fink L, Zannettino ACW. Whole Exome Sequencing of Paired MGUS\/SMM to MM Patients Reveals Novel Subclonal Tumour Evolution Models in Disease Progression of Multiple Myeloma. Blood. 2017; 130: 391.","DOI":"10.1182\/blood.V130.Suppl_1.391.391"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Lagana A, Melnekoff D, Beno I, Leshchenko V, Perumal D, Keats JJ, et al. Clonal Evolution in Newly Diagnosed Multiple Myeloma Patients: A Follow-up Study from the MMRF Compass Genomics Project. Blood. 2017; 130: 325.","DOI":"10.1182\/blood.V130.Suppl_1.325.325"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Wenric S, Sticca T, Caberg JH, Josse C, Fasquelle C, Herens C, et al. Exome copy number variation detection: Use of a pool of unrelated healthy tissue as reference sample. Genetic Epidemiology. 2017; 41: 35\u201340.","DOI":"10.1002\/gepi.22019"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Bryant D, Tapper W, Weston-Bell NJ, Bolomsky A, Song L, Xu S, et al. Single Cell Whole Exome Sequencing in an Index Case of Amp1q21 Multiple Myeloma to Define Intraclonal Variation. Blood. 2016; 128: 5651.","DOI":"10.1182\/blood.V128.22.5651.5651"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Miller A, Cattaneo L, Asmann YW, Braggio E, Keats JJ, Auclair D, et al. Correlation Between Somatic Mutation Burden, Neoantigen Load and Progression Free Survival in Multiple Myeloma: Analysis of MMRF CoMMpass Study. Blood. 2016; 128: 193.","DOI":"10.1182\/blood.V128.22.193.193"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Walker BA, Samur MK, Mavrommatis K, Ashby C, Wardell CP, Ortiz M, et al. The Multiple Myeloma Genome Project: Development of a Molecular Segmentation Strategy for the Clinical Classification of Multiple Myeloma. Blood. 2016; 128: 196.","DOI":"10.1182\/blood.V128.22.196.196"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Weinhold N, Ashby C, Rasche L, Chavan SS, Stein C, Stephens OW, et al. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood. 2016; 128: 1735\u20131744.","DOI":"10.1182\/blood-2016-06-723007"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Munshi NC, Bolli N, Minvielle S, Anderson KC, Parmigiani G, Campbell P, et al. Next Generation Sequencing in Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia. 2015; 15: e2\u2013e3.","DOI":"10.1016\/j.clml.2015.08.004"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Walker BA, Wardell CP, Melchor L, Hulkki S, Potter NE, Johnson DC, et al. Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood. 2012; 120: 1077\u20131086.","DOI":"10.1182\/blood-2012-03-412981"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Munshi NC, Avet-Loiseau H, Stephens PJ, Bignell GR, Tai YT, Shammas M, et al. Whole Genome Sequencing Defines the Clonal Architecture and Genomic Evolution in Myeloma: Tumor Heterogeneity with Continued Acquisition of New Mutational Change. Blood. 2011; 118: 297.","DOI":"10.1182\/blood.V118.21.297.297"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Bolli N, Li Y, Sathiaseelan V, Raine K, Jones D, Ganly P, et al. A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma. Blood Cancer Journal. 2016; 6: e467.","DOI":"10.1038\/bcj.2016.72"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Manier S, Salem K, Glavey SV, Roccaro AM, Ghobrial IM. Genomic Aberrations in Multiple Myeloma. Cancer Treatment and Research. 2016; 169: 23\u201334.","DOI":"10.1007\/978-3-319-40320-5_3"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Zielinska AK, Leigh K, Gomez H, Van Laar RK. Validation of the Nextseq 500 and Development of a High-Throughput NGS Pipeline for Identifying Clinically-Relevant Gene Variants in Multiple Myeloma Specimens. Blood. 2015; 126: 5346.","DOI":"10.1182\/blood.V126.23.5346.5346"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Bolli N, Bignell GR, Ganly P, Papaemmanuil E, Avet-Loiseau H, Sperling A, et al. A Next Generation Sequencing-Based Approach to Detect Gene Mutations, Copy Number Changes and IGH Translocations in Multiple Myeloma. Blood. 2014; 124: 3364.","DOI":"10.1182\/blood.V124.21.3364.3364"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022; 36: 1703\u20131719.","DOI":"10.1038\/s41375-022-01613-1"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Medina A, Puig N, Flores-Montero J, Jimenez C, Sarasquete ME, Garcia-Alvarez M, et al. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma. Blood Cancer Journal. 2020; 10: 108.","DOI":"10.1038\/s41408-020-00377-0"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Ha J, Lee H, Shin S, Cho H, Chung H, Jang JE, et al. Ig Gene Clonality Analysis Using Next-Generation Sequencing for Improved Minimal Residual Disease Detection with Significant Prognostic Value in Multiple Myeloma Patients. The Journal of Molecular Diagnostics : JMD. 2022; 24: 48\u201356.","DOI":"10.1016\/j.jmoldx.2021.09.006"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Ho C, Syed M, Roshal M, Petrova-Drus K, Moung C, Yao JJ, et al. Next-Generation Sequencing-Based Assay Shows High Clonal Characterization Success Rate for Plasma Cell Neoplasms, and Concordance with Flow Cytometry in Minimal Residual Disease Detection. Blood. 2018; 132: 4475.","DOI":"10.1182\/blood-2018-99-115690"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Kim M, Kim HJ, Lee YK. IGH and IGK Rearrangement and IGH Somatic Hypermutation Analysis Using Next-generation Sequencing for the Detection of Clonality in High-risk Korean Multiple Myeloma Patients. Clinical Lymphoma Myeloma and Leukemia. 2019; 19: e68\u2013e69.","DOI":"10.1016\/j.clml.2019.09.108"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Rustad EH, Yellapantula VD, Glodzik D, Maclachlan KH, Diamond B, Boyle EM, et al. Revealing the impact of structural variants in multiple myeloma. Blood Cancer Discovery. 2020; 1: 258\u2013273.","DOI":"10.1158\/2643-3230.BCD-20-0132"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Yao Q, Bai Y, Kumar S, Au E, Orfao A, Chim CS. Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma: A Comparison With Real-Time Quantitative PCR. Frontiers in Oncology. 2021; 10: 611021.","DOI":"10.3389\/fonc.2020.611021"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Yao Q, Bai Y, Orfao A, Chim CS. Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma. Frontiers in Oncology. 2019; 9: 449.","DOI":"10.3389\/fonc.2019.00449"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM, et al. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2015; 33: 3911\u20133920.","DOI":"10.1200\/JCO.2014.59.1503"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Raab MS, Giesen N, Scheid C, Besemer B, Miah K, Benner A, et al. Safety and Preliminary Efficacy Results from a Phase II Study Evaluating Combined BRAF and MEK Inhibition in Relapsed\/Refractory Multiple Myeloma (rrMM) Patients with Activating BRAF V600E Mutations: The GMMG-Birma Trial. Blood. 2020; 136: 44\u201345.","DOI":"10.1182\/blood-2020-142600"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Yellapantula V, Hultcrantz M, Rustad EH, Wasserman E, Londono D, Cimera R, et al. Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma. Blood Cancer Journal. 2019; 9: 101.","DOI":"10.1038\/s41408-019-0264-y"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Yellapantula V, Hultcrantz M, Rustad EH, Landau HJ, Iacobuzio-Donahue C, Akhlaghi T, et al. Mytype: A Capture Based Sequencing Approach to Detect Somatic Mutations, Copy Number Changes and IGH Translocations in Multiple Myeloma. Blood. 2018; 132: 5588.","DOI":"10.1182\/blood-2018-99-119886"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Wardell C, Alpe TL, Farmer P, Rutherford MW, Wang Y, Weinhold N, et al. Extracting Prognostic Molecular Information from PET-CT Imaging of Multiple Myeloma Using Radiomic Approaches. Blood. 2018; 132: 1906.","DOI":"10.1182\/blood-2018-99-117103"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Fiala M, Dukeman J, Stockerl-Goldstein K, Tomasson M, Wildes T, Auclair D, et al. Next Generation Sequencing Based Revised International Staging System (R-ISS) for Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia. 2017; 17: e18.","DOI":"10.1016\/j.clml.2017.03.030"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Perumal D, Lagana\u2019 A, Melnekoff D, Readhead B, Kidd B, Leshchenko VV, et al. Network Modeling Reveals CDC42BPA and CLEC11A As Novel Driver Genes of t(4; 14) Multiple Myeloma. Blood. 2016; 12: 802.","DOI":"10.1182\/blood.V128.22.802.802"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Stephenson K, Benard B, Klug M, Christofferson A, Keats JJ. Clonal Diversity of a Myeloma Tumor: From Generations of Cells to Treatment Implications. Blood. 2014; 124: 3424.","DOI":"10.1182\/blood.V124.21.3424.3424"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Melchor L, Walker BA, Wardell CP, Brioli A, Kaiser MF, L\u00f3pez-Corral L, et al. Intra-Clonal Heterogeneity Is a Critical Early Event in the Preclinical Stages of Multiple Myeloma and Is Subject to Darwinian Fluctuation throughout the Disease. Blood. 2012; 120: 3941.","DOI":"10.1182\/blood.V120.21.3941.3941"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Hultcrantz M, Rustad EH, Yellapantula V, Jacob A, Akhlaghi T, Korde N, et al. Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. 2022; 28: 2160\u20132166.","DOI":"10.1158\/1078-0432.CCR-20-2995"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Hultcrantz M, Rustad EH, Yellapantula V, Arcila M, Ho C, Syed MH, et al. Baseline VDJ clonotype detection using a targeted sequencing NGS assay: allowing for subsequent MRD assessment. Blood Cancer Journal. 2020; 10: 76.","DOI":"10.1038\/s41408-020-00343-w"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Hultcrantz M, Rustad EH, Yellapantula V, Akhlaghi T, Jacob A, Patel A, et al. Capture Rate of the Adaptive Next Generation Sequencing VDJ Assay in Multiple Myeloma. Blood. 2018; 132: 3184.","DOI":"10.1182\/blood-2018-99-118768"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Rustad EH, Hultcrantz M, Yellapantula VD, Akhlaghi T, Ho C, Arcila ME, et al. V(D)J Sequence Capture for DNA-Based Minimal Residual Disease Detection in Multiple Myeloma. Blood. 2018; 132: 4444.","DOI":"10.1182\/blood-2018-99-113889"}],"container-title":["Frontiers in Bioscience-Scholar"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/FBS\/18\/3\/10.31083\/FBS44690","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:26:56Z","timestamp":1790699216000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/FBS\/18\/3\/10.31083\/FBS44690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"alternative-id":["S1945-0524(26)03796-0"],"URL":"https:\/\/doi.org\/10.31083\/fbs44690","relation":{},"ISSN":["1945-0516","1945-0524"],"issn-type":[{"value":"1945-0516","type":"print"},{"value":"1945-0524","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"article-number":"44690"}}